A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer (Tamarack)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05551117 |
|
Recruitment Status :
Recruiting
First Posted : September 22, 2022
Last Update Posted : May 31, 2023
|
Sponsor:
MacroGenics
Information provided by (Responsible Party):
MacroGenics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Study CP-MGC018-03 is a randomized, open-label, Phase 2 study. The study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). ARAT includes abiraterone, enzalutamide, or apalutamide. Participants may have received up to 1 prior taxane-containing regimen, but no other chemotherapy agents.
The study will assess efficacy and tolerability of two vobramitamab duocarmazine (MGC018) experimental arms (2.0 mg/kg every 4 weeks [Q4W] and 2.7 mg/kg Q4W) . Approximately 100 participants will be randomized 1:1.
Vobramitamab duocarmazine will be administered intravenously (IV) in clinic on Day 1 of each 4-week cycle. Vobramitamab duocarmazine will be administered for up to 26 cycles, approximately 2 years, until criteria for treatment discontinuation are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. Routine examinations and blood tests will be performed and evaluated by the study doctor.
An analysis of radiographic progression-free survival (rPFS) will o after 100 participants have been on-study for at least 6 months.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Castration-Resistant Prostatic Cancer Androgen-Independent Prostatic Cancer Androgen-Insensitive Prostatic Cancer Androgen-Resistant Prostatic Cancer Hormone Refractory Prostatic Cancer | Biological: vobramitamab duocarmazine 2.0 mg (Arm A) Biological: vobramitamab duocarmazine 2.7 mg (Arm B) | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Randomized, Open-label, Study of Two Dose Levels of Obramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer |
| Estimated Study Start Date : | May 2023 |
| Estimated Primary Completion Date : | December 2026 |
| Estimated Study Completion Date : | December 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Prostate cancer
MedlinePlus related topics:
Prostate Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: MGC018 2.0 mg (Arm A)
MGC018 2.0 mg/kg every 4 weeks
|
Biological: vobramitamab duocarmazine 2.0 mg (Arm A)
2.0 mg/kg intravenous (IV) every 4 weeks
Other Name: MGC018 |
|
Experimental: MGC018 2.7 mg (Arm B)
MGC018 2.7 mg/kg every 4 weeks
|
Biological: vobramitamab duocarmazine 2.7 mg (Arm B)
2.7 mg.kg IV every 4 weeks
Other Name: MGC018 |
Primary Outcome Measures :
- Radiographic progression free survival (rPFS) as determined by the investigator [ Time Frame: Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years ]The rPFS is defined as the time from the date of randomization to the date of first documented progressive disease (PD) per Prostate Cancer Working Group 3 (PCWG3) or death from any cause, whichever occurs first. Three arms will be compared: Arm A, Arm B, and control.
Secondary Outcome Measures :
- Objective response rate (ORR) by PCWG3 criteria using investigator review [ Time Frame: Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years ]The number of participants experiencing a complete response (CR) or partial response (PR) to treatment.
- Duration of response (DoR) per PCWG3 criteria using investigator review [ Time Frame: Every 8 weeks throughout study participation, up to 2 years ]The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.
- Prostate-specific Cancer Antigen (PSA) response rate per PCWG3 criteria [ Time Frame: Every 4 weeks throughout study participation, up to 2 years ]PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.
- Time to PSA progression per PCWG3 criteria [ Time Frame: Every 4 weeks throughout study participation, up to 2 years ]
In participants with a decrease in PSA from baseline: ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥ 3 weeks later.
In participants with no decrease in PSA from baseline: ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12 weeks.
- Duration of PSA response per PCWG3 criteria [ Time Frame: Every 4 weeks throughout study participation, up to 2 years ]Duration of PSA response is defined as the time from the date of first documented PSA response to the earliest date of PSA progression.
- PSA percent change over time [ Time Frame: Every 4 weeks throughout study participation, up to 2 years ]
- Best PSA percent change [ Time Frame: Every 4 weeks throughout study participation, up to 2 years ]
- Time to first symptomatic skeletal event (SSE) [ Time Frame: Every 4 weeks throughout the study, up to 2 years ]An SSE is defined as any of the following events: new symptomatic pathological fracture, requirement for radiation therapy to relieve bone pain, spinal cord compression, or tumor-related orthopedic surgical intervention. The time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE.
- Number of participants with adverse event (AEs), serious AEs (SAEs), and AEs leading to study treatment discontinuation. [ Time Frame: Throughout the study, up to 2 years ]
- Number of participants who develop anti-drug antibodies [ Time Frame: Throughout the study, up to 2 years ]
- maximum concentration or concentration at the end of infusion (Cmax) [ Time Frame: Cycle 1, Day 1: Predose, end of infusion (EOI [1 hour]), 2-4 hours after EOI, 6-8 hours after EOI, and Cycle 1 Day 15. Pre-infusion and EOI on Cycle 2 Days 1, Cycle 2 Day 15; Pre-infusion and EOI on Day 1 of Cycles 3, 4, 5, 6, 9 and 12 (28-day cycle) ]The highest measured concentration of vobramitamab duocarmazine in the bloodstream.
- area under the concentration time curve (AUC) [ Time Frame: Cycle 1, Day 1: Predose, end of infusion (EOI [1 hour]), 2-4 hours after EOI, 6-8 hours after EOI, and Cycle 1 Day 15. Pre-infusion and EOI on Cycle 2 Days 1, Cycle 2 Day 15; Pre-infusion and EOI on Day 1 of Cycles 3, 4, 5, 6, 9 and 12 (28-day cycle) ]AUC is the total amount of vobramitamab duocarmazine in bloodstream after drug administration
- Trough drug concentration (Ctrough or Cmin) [ Time Frame: Cycle 1, Day 1: Predose, end of infusion (EOI [1 hour]), 2-4 hours after EOI, 6-8 hours after EOI, and Cycle 1 Day 15. Pre-infusion and EOI on Cycle 2 Days 1, Cycle 2 Day 15; Pre-infusion and EOI on Day 1 of Cycles 3, 4, 5, 6, 9 and 12 (28-day cycle) ]Trough concentration is the concentration measured before a subsequent dose of vobramitamab duocarmazine
- Clearance (CL) [ Time Frame: Cycle 1, Day 1: Predose, end of infusion (EOI [1 hour]), 2-4 hours after EOI, 6-8 hours after EOI, and Cycle 1 Day 15. Pre-infusion and EOI on Cycle 2 Days 1, Cycle 2 Day 15; Pre-infusion and EOI on Day 1 of Cycles 3, 4, 5, 6, 9 and 12 (28-day cycle) ]Drug clearance is the amount of drug removed from the bloodstream by the body per unit of time
- Volume of distribution (Vz) [ Time Frame: Cycle 1, Day 1: Predose, end of infusion (EOI [1 hour]), 2-4 hours after EOI, 6-8 hours after EOI, and Cycle 1 Day 15. Pre-infusion and EOI on Cycle 2 Days 1, Cycle 2 Day 15; Pre-infusion and EOI on Day 1 of Cycles 3, 4, 5, 6, 9 and 12 (28-day cycle) ]The volume of distribution is related to how much drug is distributed to body tissues, or remains in the bloodstream.
- Terminal half-life [ Time Frame: Cycle 1, Day 1: Predose, end of infusion (EOI [1 hour]), 2-4 hours after EOI, 6-8 hours after EOI, and Cycle 1 Day 15. Pre-infusion and EOI on Cycle 2 Days 1, Cycle 2 Day 15; Pre-infusion and EOI on Day 1 of Cycles 3, 4, 5, 6, 9 and 12 (28-day cycle) ]Terminal elimination half-life is the time it takes for the concentration of the drug in plasma or serum to be reduced by 50%
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features.
- Participants must have ≥ 1 metastatic lesion that is present on magnetic resonance imaging (MRI), computed tomography (CT), or bone scan obtained ≤ 28 days prior to initiation of study treatment.
- Tumor progression at study entry documented by PSA or imaging per PCWG3 criteria
- Received 1 prior ARAT for metastatic or non-metastatic, castration-sensitive or castration-resistant prostate cancer. A second ARAT regimen of <60 days used as bridging to lutetium-177 is permitted.
- Availability of archival or formalin-fixed paraffin-embedded (FFPE) tumor tissue sample for participants with metastasis to internal organs
- Acceptable physical condition and laboratory values.
Exclusion Criteria:
- Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
- Received >1 prior taxane-containing regimen for prostate cancer. A second taxane regimen of <60 days used as bridging for lutetium-177 is permitted.
- Received >3 total prior therapies for mCRPC
- Participants with known BRCA or ATM mutation (germline or somatic) are not eligible unless they received prior treatment with a PARP inhibitor where available, indicated and tolerated.
- Another hematologic or solid tumor ≥ stage 1 malignancy that completed surgery, last dose of radiotherapy, or last dose of systemic anti-cancer therapy ≤ 2 years from first dose of study treatment. Participants who had curative therapy for non-melanomatous skin cancer or for localized malignancy are eligible.
- Untreated, symptomatic central nervous system (CNS) metastasis.
- Prior treatment with any B7-H3 targeted agent for cancer,
- Contradictions to the use of corticosteroid treatment
- Prior stem cell, tissue, or solid organ transplant.
- Use of products that have published anti-prostate cancer activity or are known to decrease PSA.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05551117
Contacts
| Contact: Global Trial Manager | 301-251-5172 | info@macrogenics.com |
Locations
Show 21 study locations
Sponsors and Collaborators
MacroGenics
Investigators
| Study Director: | Ashley Ward, M.D. | MacroGenics |
| Responsible Party: | MacroGenics |
| ClinicalTrials.gov Identifier: | NCT05551117 |
| Other Study ID Numbers: |
CP-MGC018-03 |
| First Posted: | September 22, 2022 Key Record Dates |
| Last Update Posted: | May 31, 2023 |
| Last Verified: | April 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Prostatic Neoplasms, Castration-Resistant Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms |
Genital Diseases, Male Genital Diseases Urogenital Diseases Prostatic Diseases Male Urogenital Diseases |